Clariant, a Swiss multinational speciality chemical company, is expanding its Clear Lake, TX site to include excipient GMP-compliant manufacturing of pharmaceutical-grade polyethylene glycol (PEG) excipients, significantly improving their availability and reliability for North American customers, with extended reach to Latin America.

The multi-phase expansion aims to address critical industry priorities around supply-chain security, continuity, and responsiveness as well as the company’s strategic commitment to the U.S. pharmaceutical market.

The Clear Lake facility represents Clariant’s first U.S. manufacturing site dedicated to producing pharmaceutical-grade PEG excipients. By establishing regional production capabilities, Clariant aims to create a more resilient, responsive supply chain infrastructure for pharmaceutical manufacturers across the region.

“This expansion strengthens our ability to provide reliable local supply and positions us as a true partner to the North American pharmaceutical industry,” said Vaios Barlas, Head of Health Care at Clariant. “In addition to greater manufacturing capacity, we’re fundamentally transforming how we serve our customers by bringing production closer to their operations and accelerating more responsive, collaborative relationships.”

The Clear Lake facility upgrade and operations were designed to meet the pharmaceutical industry’s rigorous quality, safety, and regulatory expectations. Excipient GMP compliance ensures that all manufacturing processes align with international pharmaceutical excipient standards, providing customers with the documentation, traceability, and quality assurance required for regulated pharmaceutical production.

According to the company, its pharmaceutical-grade PEGs are registered in relevant pharmacopoeias and feature negligible toxicity profiles, making them suitable for a wide range of applications.